完全切除的非小细胞肺癌中肿瘤突变负荷的预后影响
该研究对2013至2016年在福岛医科大学医院接受手术的90例非小细胞肺癌患者进行全外显子测序计算肿瘤突变负荷(TMB),分析其与预后的相关性。结果显示TMB大于62与更差的总生存显著相关(HR=6.633,p=0.0003),多因素分析中高TMB亦为不良预后因素(HR=12.31,p=0.019)。在I期患者中,高TMB与更差的总生存(HR=7.582,p=0.0018)和无病生存(HR=6.07,p=0.0072)相关。
要点
- TMB>62与完全切除NSCLC患者更差的总生存相关(HR=6.633,p=0.0003)。
- 多因素分析显示高TMB为独立不良预后因素(HR=12.31,p=0.019)。
- I期NSCLC中高TMB与更差的总生存和无病生存相关。
核心结论
- 非小细胞肺癌中高肿瘤突变负荷是不良预后因素。
研究设计与样本
- 研究纳入2013至2016年在福岛医科大学医院接受手术的90例NSCLC患者,术前均未接受化疗或免疫治疗。
- 通过下一代测序的全外显子测序分析计算个体肿瘤的TMB,评估TMB与预后的相关性。
主要发现
- TMB大于62与NSCLC患者更差的总生存相关(HR=6.633,p=0.0003)。
- 多因素分析显示高TMB与不良预后相关(HR=12.31,p=0.019)。
- 在I期NSCLC患者中,较高TMB与更差的总生存(HR=7.582,p=0.0018)和无病生存(HR=6.07,p=0.0072)相关。
临床怎么用
- 高TMB可作为完全切除NSCLC的不良预后标志,提示术后辅助免疫检查点抑制剂治疗可能改善复发和总生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tumor mutation burden (TMB) is thought to be associated with the amount of neoantigen in the tumor and to have an important role in predicting the effect of immune checkpoint inhibitors. However, the relevance of TMB to prognosis is not yet fully understood. In this study, we investigated the clinical significance of TMB in patients with NSCLC and examined the relationship between TMB and prognosis. METHODS: We calculated TMB within individual tumors by whole-exome sequencing analysis using next-generation sequencing. We included that there were 90 patients with NSCLC who underwent surgery in the Hospital of Fukushima Medical University from 2013 to 2016. No patients received chemotherapy or immunotherapy before surgery. We assessed the correlation between TMB and prognosis. RESULTS: TMB greater than 62 was associated with worse overall survival (OS) of patients with NSCLC (hazard ratio [HR] = 6.633, p = 0.0003). Multivariate analysis showed poor prognosis with high TMB (HR = 12.31, p = 0.019). In patients with stage I NSCLC, higher TMB was associated with worse prognosis for both OS (HR = 7.582, p = 0.0018) and disease-free survival (HR = 6.07, p = 0.0072). CONCLUSIONS: High TMB in NSCLC is a poor prognostic factor. If high TMB is a predictor of the efficacy of immune checkpoint inhibitors, postoperative adjuvant therapy with immune checkpoint inhibitors may contribute to improvement of recurrence and OS.
引用
- Owada-Ozaki Y, Muto S, Takagi H, et al. Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report. J Thorac Oncol. 2018. PMID: 29654927. doi:10.1016/j.jtho.2018.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。